Umlaut.bio raises EUR 3 M

Umlaut.bio is developing small molecules that target transfer RNA modifications for cancer and inflammatory diseases. The entry of BaseLaunch brings its pre-seed round to around EUR 3 million to advance its work.

Announced on
Round
Pre-seed
Amount
EUR 3 M
Location
canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic